A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

Annals of Neurology
R G MillerS C Stromatt

Abstract

Preclinical investigations indicated that recombinant human ciliary neurotrophic factor (rhCNTF) may have potential as therapy for amyotrophic lateral sclerosis (ALS). We evaluated the safety and efficacy of rhCNTF in a prospective, double-blind, placebo-controlled trial in 570 patients with ALS. Patients were randomized to receive 0.5, 2, or 5 micrograms/kg/day rhCNTF, or placebo, for 6 months. The primary efficacy end point was the change from baseline to the last on-treatment value of a combination megascore for limb strength (maximum voluntary isometric contraction) and pulmonary function. Secondary end points included individual arm and leg megascores, pulmonary function tests, an activities-of-daily-living outcome measure, and survival. The four treatment groups were similar at baseline with respect to age, sex, disease duration, and muscle strength values. At all doses tested, rhCNTF had no beneficial effect on the primary or secondary end points. Certain adverse events, as follows, appeared to be dose related: injection site reactions, cough, asthenia, nausea, anorexia, weight loss, and increased salivation. There was an increased number of deaths at the highest dose level. rhCNTF had no beneficial effect on any measure...Continue Reading

Citations

Jan 10, 2002·Annals of Neurology·Stuart C Apfel
Sep 1, 1996·Annals of Neurology·E C Yuen, W C Mobley
Nov 30, 2000·Current Treatment Options in Neurology·B M Demaerschalk, M J Strong
Feb 21, 2008·Neuromolecular Medicine·Mary E McCrate, Brian K Kaspar
May 15, 2012·Journal of Molecular Neuroscience : MN·Samira FargaliStephen R Salton
Sep 10, 2011·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Genevieve Gowing, Clive N Svendsen
Jun 27, 2003·European Journal of Pharmacology·Ajit G ThomasBarbara S Slusher
Sep 10, 1997·Journal of the Neurological Sciences·M Gourie-DeviD K Subbakrishna
Jan 7, 1998·Journal of the Neurological Sciences·G D Borasio
Dec 16, 1998·Journal of the Neurological Sciences·J B KurekE Byrne
May 17, 2000·Pharmaceutica acta Helvetiae·M W SleemanS J Wiegand
Jan 1, 1997·Clinical Therapeutics·H AllainS Belliard
Jun 5, 2003·Pharmacology & Therapeutics·Michael J Strong
Jun 26, 1998·Brain Research. Brain Research Reviews·B Connor, M Dragunow
Jun 1, 1997·Trends in Pharmacological Sciences·E LouvelA Doble
May 22, 2003·Progress in Neurobiology·Hitoshi YasudaRyuichi Kikkawa
Jul 8, 1998·Progress in Neurobiology·W T Hermens, J Verhaagen
Jan 1, 2003·Brain Research Bulletin·T L ButlerK R Pennypacker
Oct 1, 1996·Current Opinion in Neurobiology·J D Rothstein
Dec 4, 2012·Acta Pharmacologica Sinica·Philippe M D'Onofrio, Paulo D Koeberle
Apr 5, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·James C DodgeBrian K Kaspar
Sep 23, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·James C DodgeBrian K Kaspar
Dec 18, 2009·British Medical Bulletin·Richard W Orrell
Mar 3, 2007·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Brandi K OrmerodMaeve A Caldwell
Jan 5, 2011·Journal of Obesity·Lorenzo IughettiBarbara Predieri
Aug 16, 2006·Neuro-degenerative Diseases·Eva Ekestern

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.